Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan 15;209(2):224-225.
doi: 10.1164/rccm.202308-1355LE.

Pharmacological Interpretation of the Efficacy of Ensifentrine in Chronic Obstructive Pulmonary Disease: Insights from ENHANCE Trials

Luigino Calzetta  1 , Mario Cazzola  2 , Paola Rogliani  2
Affiliations
Comment

Pharmacological Interpretation of the Efficacy of Ensifentrine in Chronic Obstructive Pulmonary Disease: Insights from ENHANCE Trials

Luigino Calzetta et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment in

  • Reply to Gan et al., to Calzetta et al., and to Poor.
    Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Anzueto A, et al. Am J Respir Crit Care Med. 2024 Jan 15;209(2):226-228. doi: 10.1164/rccm.202309-1657LE. Am J Respir Crit Care Med. 2024. PMID: 37939377 Free PMC article. No abstract available.

Comment on

References

    1. Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE Trials) Am J Respir Crit Care Med . 2023;208:406–416. - PMC - PubMed
    1. Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbröker D, Bethke TD. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet . 2005;366:563–571. - PubMed
    1. Calzetta L, Pistocchini E, Chetta A, Rogliani P, Cazzola M. Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval. Expert Opin Investig Drugs . 2023;32:525–536. - PubMed
    1. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov . 2014;13:290–314. - PMC - PubMed
    1. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. FLAME Investigators Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med . 2016;374:2222–2234. - PubMed

MeSH terms